A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
Daniel Haszard says: 
Cyber Attacks On Banks More Serious Than Public Realizes
E&O Insights: Restaurant and Tavern Risks
CEA’s First CIO Reflects C-Suite Trend
Golf and Country Clubs Weather the Storm
Midwest AGs Go After Storm-Chasing Roofing Companies
Medical Malpractice Payouts Not Driving Up Health Costs: Study
Florida Lawmakers Approve Medical Malpractice Reform
Industry Results Show Positive Signs for Workers’ Comp Line, NCCI’s Chief Economist Says
Sign up to receive insurance news alerts!
